Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus

Annals of Internal Medicine

Volumn 132, Issue 8, 2000, Pages 612-620

  Rudolph, Rebecca E ^a,b   Vaughan, Thomas L ^b   Storer, Barry E ^b   Haggitt, Rodger C ^c   Rabinovitch, Peter S ^a   Levine, Douglas S ^d   Reid, Brian J ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b USA   (United States)

^c UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER RISK; CONTROLLED STUDY; DISEASE SEVERITY; ESOPHAGUS CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0034681971     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-132-8-200004180-00003     Document Type: Article

References (48)

1. Fitzgerald RC, Triadafilopoulos G. Recent developments in the molecular characterization of Barrett's esophagus Dig Dis. 1998;16:63-80.
2. Spechler SJ, Zeroogian JM, Antonioli DA, Wang HH, Goyal RK. Prevalence of metaplasia at the gastro-oesophageal junction. Lancet. 1994;344: 1533-6.
3. Weston AP, Krmpotich P, Makdisi WF, Cherian R, Dixon A, McGregor DH, et al. Short segment Barrett's esophagus: clinical and histological features, associated endoscopic findings, and association with gastric intestinal metaplasia. Am J Gastroenterol. 1996;91:981-6.
4. Morales TG, Sampliner RE, Bhattacharyya A. Intestinal metaplasia of the gastric cardia. Am J Gastroenterol. 1997;92:414-8.
5. Hirota WK, Loughney TM, Lazas DJ, Maydonovitch CL, Rholl V, Wong RK. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. Gastroenterology. 1999;116:277-85.
6. Johnston MH, Hammond AS, Laskin W, Jones DM. The prevalence and clinical characteristics of short segments of specialized intestinal metaplasia in the distal esophagus on routine endoscopy. Am J Gastroenterol. 1996;91: 1507-11.
7. Chalasani N, Wo JM, Hunter JG, Waring JP. Significance of intestinal metaplasia in different areas of esophagus including esophagogastric junction. Dig Dis Sci. 1997;42:603-7.
8. Hameeteman W, Tytgat GN, Houthoff HJ, van den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology. 1989;96:1249-56.
9. Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut. 1991;32:1441-6.
10. Williamson WA, Ellis FH Jr, Gibb SP, Shahian DM, Aretz HT, Heatley GJ, et al. Barrett's esophagus. Prevalence and incidence of adenocarcinoma. Arch Intern Med. 1991;151:2212-6.
11. van der Burgh A, Dees J, Hop WC, van Blankenstein M. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut. 1996;39:5-8.
12. Spechler SJ, Goyal RK. The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett. Gastroenterology. 1996;110:614-21.
13. Iftikhar SY, James PD, Steele RJ, Hardcastle JD, Atkinson M. Length of Barrett's oesophagus: an important factor in the development of dysplasia and adenocarcinoma. Gut. 1992;33:1155-8.
14. Menke-Pluymers MB, Hop WC, Dees J, van Blankenstein M, Tilanus HW. Risk factors for the development of an adenocarcinoma in columnarlined (Barrett) esophagus. The Rotterdam Esophageal Tumor Study Group. Cancer. 1993;72:1155-8.
15. Hamilton SR, Smith RR, Cameron JL. Prevalence and characteristics of Barrett esophagus in patients with adenocarcinoma of the esophagus or esophagogastric junction. Hum Pathol. 1988;19:942-8.
16. Schnell TG, Sontag SJ, Chejfec G. Adenocarcinomas arising in tongues or short segments of Barrett's esophagus. Dig Dis Sci. 1992;37:137-43.
17. Cameron AJ, Lomboy CT, Pera M, Carpenter HA. Adenocarcinoma of the esophagogastric junction and Barrett's esophagus. Gastroenterology. 1995; 109:1541-6.
18. Sharma P, Morales TG, Bhattacharyya A, Garewal HS, Sampliner RE. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up. Am J Gastroenterol. 1997;92:2012-6.
19. Farrow DC, Vaughan TL. Determinants of survival following the diagnosis of esophageal adenocarcinoma (United States). Cancer Causes Control. 1996; 7:322-7.
20. Streitz JM Jr, Andrews CW Jr, Ellis FH Jr. Endoscopic surveillance of Barrett's esophagus. Does it help? J Thorac Cardiovasc Surg. 1993;105:383-7.
21. Lerut T, Coosemans W, Van Raemdonck D, Dillemans B, De Leyn P, Marnette JM, et al. Surgical treatment of Barrett's carcinoma. Correlations between morphologic findings and prognosis. J Thorac Cardiovasc Surg. 1994;107:1059-65.
22. Rusch VW, Levine DS, Haggitt R, Reid BJ. The management of high grade dysplasia and early cancer in Barrett's esophagus. A multidisciplinary problem. Cancer. 1994;74:1225-9.
23. Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the Amencan College of Gastroenterology. Am J Gastroenterol. 1998;93:1028-32.
24. Cameron AJ. Management of Barrett's esophagus. Mayo Clin Proc. 1998; 73:457-61.
25. Riddell RH. Early detection of neoplasia of the esophagus and gastroesophageal junction. Am J Gastroenterol. 1996;91:853-63.
26. Beck IT, Champion MC, Lemire S, Thomson AB, Anvari M, Armstrong D, et al. The Second Canadian Consensus Conference on the management of patients with gastroesophageal reflux disease. Can J Gastroenterol. 1997; 11(Suppl B):7B-20B.
27. Reid BJ, Barrett MT, Galipeau PC, Sanchez CA, Neshat K, Cowan DS, et al. Barrett's esophagus: ordering the events that lead to cancer. Eur J Cancer Prev. 1996;5(Suppl 2):57-65.
28. Harle IA, Finley RJ, Belsheim M, Bondy DC, Booth M, Lloyd D, et al. Management of adenocarcinoma in a columnar-lined esophagus. Ann Thorac Surg. 1985;40:330-6.
29. Streitz JM Jr, Ellis FH Jr, Gibb SP, Balogh K, Watkins E Jr. Adenocarcinoma in Barrett's esophagus. A clinicopathologic study of 65 cases. Ann Surg. 1991;213:122-5.
30. Achkar E, Carey W. The cost of surveillance for adenocarcinoma complicating Barrett's esophagus. Am J Gastroenterol. 1988;83:291-4.
31. Provenzale D, Kemp JA, Arora S, Wong JB. A guide for surveillance of patients with Barrett's esophagus. Am J Gastroenterol. 1994;89:670-80.
32. Reid BJ, Blount PL, Rubin CE, Levine DS, Haggitt RC, Rabinovitch PS. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology. 1992;102:1212-9.
33. Levine DS, Reid BJ. Endoscopic biopsy technique for acquiring larger mucosal samples. Gastrointest Endosc. 1991;37:332-7.
34. Reid BJ, Haggitt RC, Rubin CE, Rabinovitch PS. Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology. 1987;93:1-11.
35. Levine DS, Haggitt RC, Blount PL, Rabinovitch PS, Rusch VW, Reid BJ. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology. 1993;105: 40-50.
36. Reid BJ, Haggitt RC, Rubin CE, Roth G, Surawicz CM, Van Belle G, et al. Observer variation in the diagnosis of dysolasia in Barrett's esophagus. Hum Pathol. 1988;19:166-78.
37. Chow WH, Blot WJ, Vaughan TL, Risch HA, Gammon MD, Stanford JL, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst. 1998;90:150-5.
38. Stata Statistical Software: Release 5.0. College Station, TX: Stata Corp.; 1997.
39. Weston AP, Krmpotich PT, Cherian R, Dixon A, Topalosvki M. Prospective long-term endoscopic and histological follow-up of short segment Barrett's esophagus: comparison with traditional long segment Barrett's esophagus. Am J Gastroenterol. 1997;92:407-13.
40. Banerjee B, Salian N, Waits W, Ringold A, Rashid S. Risk factors for developing dysplasia or adenocarcmoma in Barrett's esophagus (BE) with implications for endoscopic surveillance [Abstract]. Gastroenterotogy. 1994;106: A45.
41. Ransom JM, Patel GK, Clift SA, Womble NE, Read RC. Extended and limited types of Barrett's esophagus in the adult. Ann Thorac Surg. 1982;33: 19-27.
42. Reid BJ, Sanchez CA, Blount PL, Levine DS. Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression Gastroenterology. 1993;105:119-29.
43. Hong MK, Laskin WB, Herman BE, Johnston MH, Vargo JJ, Steinberg SM, et al. Expansion of the Ki-67 proliferate compartment correlates with degree of dysplasia in Barrett's esophagus. Cancer. 1995;75:423-9.
44. Terpstra OT, Dahl EP, Williamson RC, Ross JS, Malt RA. Colostomy closure promotes cell proliferation and dimethylhydrazine-induced carcinogenesis in rat distal colon. Gastroenterology. 1981;81:475-80.
45. Kingsnorth AN, King WW, Diekema KA, McCann PP, Ross JS, Malt RA. Inhibition of ornithine decarboxylase with 2-difluoromethylornithine: reduced incidence of dimethylhydrazine-induced colon tumors in mice. Cancer Res. 1983;43:2545-9.
46. Ames BN, Gold LS. Too many rodent carcinogens: mitogenesis increases mutagenesis. Science. 1990;249:970-1.
47. Menke-Pluymers MB, Mulder AH, Hop WC, van Blankenstein M, Tilanus HW. Dysplasia and aneuploidy as markers of malignant degeneration in Barrett's oesophagus. The Rotterdam Oesophageal Tumour Study Group. Gut. 1994;35:1348-51.
48. Kim SL, Waring JP, Spechler SJ, Sampliner RE, Doos WG, Krol WF, et al. Diagnostic inconsistencies in Barrett's esophagus. Department of Veterans Affairs Gastroesophageal Reflux Study Group. Gastroenterology. 1994;107: 945-9.